{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:31:47Z","timestamp":1763415107963,"version":"3.40.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.revmed.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:07:51Z","timestamp":1708625271000},"page":"431-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8558","authenticated-orcid":false,"given":"A.","family":"Lescoat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rimar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Farge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2024.02.003_bib0270","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(17)32594-1","article-title":"Systemic sclerosis: advances and prospects","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.revmed.2024.02.003_bib0275","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","volume":"64","author":"Lescoat","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0280","doi-asserted-by":"crossref","first-page":"103314","DOI":"10.1016\/j.autrev.2023.103314","article-title":"Differentially expressed genes in systemic sclerosis: towards predictive medicine with new molecular tools for clinicians","volume":"22","author":"Keret","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2024.02.003_bib0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis\u00a0\u2013\u00a0associated interstitial lung disease: lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.revmed.2024.02.003_bib0290","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.02.003_bib0295","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2213-2600(19)30174-2","article-title":"Beyond silicosis, is the world failing on silica hazards?","volume":"7","author":"Cavalin","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.revmed.2024.02.003_bib0300","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/ije\/dyaa287","article-title":"Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study","volume":"50","author":"Boudigaard","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0305","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/rheumatology\/keac675","article-title":"Crystalline silica exposure in patients with rheumatoid arthritis and systemic sclerosis: a nationwide cross-sectional survey","volume":"62","author":"Cavalin","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.02.003_bib0310","doi-asserted-by":"crossref","first-page":"984907","DOI":"10.3389\/fmed.2022.984907","article-title":"Exposure to silica and systemic sclerosis: a retrospective cohort study based on the Canadian Scleroderma Research Group","volume":"9","author":"Muntyanu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.revmed.2024.02.003_bib0315","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/rheumatology\/keaa446","article-title":"Occupational silica exposure in an Australian systemic sclerosis cohort","volume":"59","author":"Patel","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.02.003_bib0320","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1093\/rheumatology\/keaa638","article-title":"The neglected association of crystalline silica exposure and systemic sclerosis","volume":"59","author":"Lescoat","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.02.003_bib0325","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.semarthrit.2020.08.014","article-title":"Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis","volume":"50","author":"Ballerie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.02.003_bib0330","first-page":"183","article-title":"Prevalence and clinical manifestations of Erasmus syndrome in systemic sclerosis: a cross-sectional study","volume":"45","author":"Azevedo","year":"2020","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.revmed.2024.02.003_bib0335","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.revmed.2024.02.003_bib0340","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2024.02.003_bib0345","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0350","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fimmu.2019.00632","article-title":"Mapping of dynamic transcriptome changes associated with silica-triggered autoimmune pathogenesis in the lupus-prone NZBWF1 mouse","volume":"10","author":"Bates","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0355","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2249.2003.02094.x","article-title":"Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice","volume":"131","author":"Brown","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2020.00219","article-title":"Crystalline silica impairs efferocytosis abilities of human and mouse macrophages: implication for silica-associated systemic sclerosis","volume":"11","author":"Lescoat","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0365","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.02.003_bib0370","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1038\/s41467-018-07425-1","article-title":"STING-dependent sensing of self-DNA drives silica-induced lung inflammation","volume":"9","author":"Benmerzoug","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.revmed.2024.02.003_bib0375","article-title":"Independent association between occupational exposure and decline of FVC in systemic sclerosis: a multicenter recruitment retrospective cohort study","author":"Thoreau","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2024.02.003_bib0380","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaad.2014.11.027","article-title":"Association of occupational exposure with features of systemic sclerosis","volume":"72","author":"Marie","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0385","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.02.003_bib0390","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2024.02.003_bib0395","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.02.003_bib0400","unstructured":"Greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans les maladies auto-immunes [Internet]. Haute Autorit\u00e9 de sant\u00e9 [cited 2023 September 4]. Available from: https:\/\/has-sante.fr\/jcms\/p_3374064\/fr\/greffe-de-cellules-souches-hematopoietiques-dans-les-maladies-auto-immunes."},{"issue":"2","key":"10.1016\/j.revmed.2024.02.003_bib0405","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.revmed.2023.12.008","article-title":"National diagnostic and care protocols (NDCP) for hematopoietic stem cell transplantation in autoimmune diseases","volume":"45","author":"Farge","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.02.003_bib0410","unstructured":"Exposition \u00e0 la silice cristalline\u00a0: des risques \u00e9lev\u00e9s pour la sant\u00e9 des travailleurs | Anses\u00a0\u2013\u00a0Agence nationale de s\u00e9curit\u00e9 sanitaire de l\u2019alimentation, de l\u2019environnement et du travail [Internet]. [cited 2020 September 3]. Available from: https:\/\/www.anses.fr\/fr\/content\/exposition-%C3%A0-la-silice-cristalline-des-risques-%C3%A9lev%C3%A9s-pour-la-sant%C3%A9-des-travailleurs."},{"key":"10.1016\/j.revmed.2024.02.003_bib0415","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrrheum.2018.34","article-title":"Systemic sclerosis: autologous HSCT is efficacious, but can we make it safer?","volume":"14","author":"Burt","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0420","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.revmed.2024.02.003_bib0425","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0430","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3899\/jrheum.200484","article-title":"Upfront combination therapy with rituximab and mycophenolate mofetil for progressive systemic sclerosis","volume":"48","author":"Rimar","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0435","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","article-title":"Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis","volume":"18","author":"Fang","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl. 113","key":"10.1016\/j.revmed.2024.02.003_bib0440","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0445","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2024.02.003_bib0450","article-title":"Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy","author":"Keret","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.02.003_bib0455","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.02.003_bib0460","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2024.02.003_bib0465","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.02.003_bib0470","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2024.02.003_bib0475","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2024.02.003_bib0480","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.02.003_bib0485","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2024.02.003_bib0490","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/BOR.0000000000000970","article-title":"Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches","volume":"35","author":"Lescoat","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.revmed.2024.02.003_bib0495","doi-asserted-by":"crossref","first-page":"102755","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2024.02.003_bib0500","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2024.02.003_bib0505","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2024.02.003_bib0510","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","author":"Merkt","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.revmed.2024.02.003_bib0515","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.02.003_bib0520","doi-asserted-by":"crossref","first-page":"5091838","DOI":"10.1155\/2016\/5091838","article-title":"Cell-based therapy for silicosis","volume":"2016","author":"Lopes-Pacheco","year":"2016","journal-title":"Stem Cells Int"},{"issue":"5","key":"10.1016\/j.revmed.2024.02.003_bib0525","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jama.2023.27885","article-title":"T-cell lymphoma From CAR T-cell therapy-a new safety notice","volume":"331","author":"Prasad","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2024.02.003_bib0530","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bjc.1980.168","article-title":"Silica-induced malignant histiocytic lymphoma: incidence linked with strain of rat and type of silica","volume":"41","author":"Wagner","year":"1980","journal-title":"Br J Cancer"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T23:19:24Z","timestamp":1720653564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0248866324000572"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.02.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}